Literature DB >> 3742155

False labelling of dopaminergic terminals in the rabbit caudate nucleus: uptake and release of [3H]-5-hydroxytryptamine.

T J Feuerstein, G Hertting, A Lupp, B Neufang.   

Abstract

The effect of the catecholamine uptake inhibitor nomifensine and of the 5-hydroxytryptamine (5-HT) uptake blocker 6-nitroquipazine on the accumulation of [3H]-5-HT (0.1 microM, 60 min incubation) and [3H]-dopamine (0.1 microM, 30 min incubation) into slices of hippocampus and caudate nucleus of the rabbit was investigated. In addition, the influence of nomifensine on the electrically evoked [3H]-5-HT release from caudate nucleus slices and of nomifensine and 6-nitroquipazine on [3H]-5-HT released from caudate nucleus slices was analysed. In hippocampal slices, which contain practically no dopaminergic but densely distributed 5-hydroxytryptaminergic and noradrenergic nerve terminals (ratio of dopamine:5-HT:noradrenaline about 1:30:25), nomifensine (1, 10 microM) did not affect the accumulation of [3H]-5-HT; 6-nitroquipazine (1 microM) reduced [3H]-5-HT uptake to about 35% of controls. In the caudate nucleus, however, where dopamine is the predominant monoamine (ratio of dopamine:5-HT:noradrenaline about 400:25:15) nomifensine (1, 10 microM) reduced the tritium accumulation to 65% whereas 6-nitroquipazine (1 microM) was ineffective. The combination of both drugs (1 microM each) led to a further decrease to about 15%. The uptake of [3H]-dopamine into hippocampal slices was blocked by both nomifensine (1 microM) and 6-nitroquipazine (1 microM) whereas in caudate nucleus slices only nomifensine (1, 10 microM) reduced the accumulation of [3H]-dopamine. The combination of both drugs was not more effective than nomifensine alone. The different effects of both uptake inhibitors in the hippocampus and caudate nucleus suggest a neurone specific rather than a substrate specific mode of action. 4 In caudate nucleus slices incubated with [3H]-5-HT and superfused continuously the electrically evoked 5-HT release was diminished by the D2-dopamine receptor agonist LY 171555 and enhanced by the D2-receptor antagonist domperidone. If, however, the labelling of caudate nucleus slices was performed in the presence of I microM or 1O microM nomifensine, the modulation of 5-HT release via D2- receptors was reduced or abolished, respectively. In the hippocampus both LY 171555 and domperidone were completely ineffective in modulating 5-HT release regardless of the absence or presence of nomifensine. 5 The present results indicate that an inverse cross labelling of [3H]-5-HT into dopaminergic and of [3H]-dopamine into 5-hydroxytryptaminergic terminals may occur despite the low concentration (0.1 microM) oftritiated transmitters used. Such cross labelling, as demonstrated with the incubation period of 60 min in the caudate nucleus, may falsely indicate the existence of D2-dopamine receptors modulating [3H]-5-HT release. If both 5-hydroxytryptaminergic and dopaminergic terminals are present within the brain region under investigation false labelling can be corrected using neuronally specific uptake inhibitors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742155      PMCID: PMC1916973          DOI: 10.1111/j.1476-5381.1986.tb10250.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Dopamine uptake in serotoninergic terminals in vitro: a valuable tool for the histochemical differentiation of catecholaminergic and serotoninergic terminals in rat cerebral structures.

Authors:  B Berger; J Glowinski
Journal:  Brain Res       Date:  1978-05-19       Impact factor: 3.252

2.  Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes.

Authors:  U Schacht; W Heptner
Journal:  Biochem Pharmacol       Date:  1974-12-15       Impact factor: 5.858

3.  Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake.

Authors:  E G Shaskan; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

4.  Characterisation of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum.

Authors:  C Ennis; J D Kemp; B Cox
Journal:  J Neurochem       Date:  1981-04       Impact factor: 5.372

5.  Effect of dopamine receptor agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro.

Authors:  K Starke; W Reimann; A Zumstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-10       Impact factor: 3.000

6.  Effect of amezinium on the release and catabolism of 3H-monoamines in brain slices.

Authors:  A Steppeler; C Döring; L Hedler; K Starke
Journal:  Biochem Pharmacol       Date:  1982-07-15       Impact factor: 5.858

7.  Role of dopamine receptors in the modulation of acetylcholine release in the rabbit hippocampus.

Authors:  H Strittmatter; R Jackisch; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

8.  Further functional in vitro comparison of pre- and postsynaptic dopamine receptors in the rabbit caudate nucleus.

Authors:  K Starke; L Späth; J D Lang; C Adelung
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-08       Impact factor: 3.000

9.  Similarities of the effects of apomorphine and 3-PPP on serotonin neurons.

Authors:  E H Lee; M A Geyer
Journal:  Eur J Pharmacol       Date:  1983-10-28       Impact factor: 4.432

10.  Dopaminergic modulation of hippocampal noradrenaline release. Evidence for alpha 2-antagonistic effects of some dopamine receptor agonists and antagonists.

Authors:  R Jackisch; S Moll; T J Feuerstein; G Hertting
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-08       Impact factor: 3.000

View more
  15 in total

1.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

2.  Neurotensin effects on evoked release of dopamine in slices from striatum, nucleus accumbens and prefrontal cortex in rat.

Authors:  E Hétier; A Boireau; P Dubédat; J C Blanchard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes.

Authors:  M Mantovani; D J Dooley; A Weyerbrock; R Jackisch; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

4.  Mathematical modelling and quantification of the autoinhibitory feedback control of noradrenaline release in brain slices.

Authors:  T J Feuerstein; W Sauermann; C Allgaier; E A Singer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

5.  An in vitro model of 1-methyl-4-phenyl-pyridinium (MPP+) toxicity: incubation of rabbit caudate nucleus slices with MPP+ followed by biochemical and functional analysis.

Authors:  T J Feuerstein; L Hedler; R Jackisch; G Hertting
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

6.  Activation of A1 adenosine receptors decreases the release of serotonin in the rabbit hippocampus, but not in the caudate nucleus.

Authors:  T J Feuerstein; K I Bär; C H Lücking
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

7.  Electrically induced release of endogenous noradrenaline and dopamine from brain slices: pseudo-one-pulse stimulation utilized to study presynaptic autoinhibition.

Authors:  A Thienprasert; E A Singer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-08       Impact factor: 3.000

8.  Characterization of the effects of serotonin on the release of [3H]dopamine from rat nucleus accumbens and striatal slices.

Authors:  B Nurse; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1988-05       Impact factor: 3.996

9.  Different effects of 1-methyl-4-phenyl-pyridinium (MPP+) on monoamine oxidase of dopaminergic terminals in caudate nucleus slices from pigmented and from albino rabbits.

Authors:  A Lupp; C H Lücking; L Hedler; T J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

10.  Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.

Authors:  M Steffens; C Engler; J Zentner; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2004-03-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.